BioMarin Announces Positive Phase 3 VOXZOGO® Study Results in Hypochondroplasia Published in NEJM Evidence

BioMarin Pharmaceutical Inc. has announced that new data from its Phase 3 CANOPY-HCH-3 study, evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia, were published in NEJM Evidence. The study demonstrated statistically significant improvements across multiple growth measures, including annualized growth velocity, standing height, height Z-score, and arm span after 52 weeks, with a safety profile consistent with previous findings.